Mallinckrodt - MNK Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00 %
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$11.40 As of 11/25/2022 01:00 AM ET

▲ +0.37 (3.35%)

Get New Mallinckrodt Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for MNK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MNK

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for Mallinckrodt in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $11.40.

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Mallinckrodt. This rating has held steady since September 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

6/6/2021

0 strong buy ratings
0 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

9/4/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/3/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/3/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/1/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/30/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/29/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/28/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
9/15/2020	Raymond James	Reiterated Rating	Hold		Low
9/14/2020	SVB Leerink	Lower Target	Market Perform	$2.00 ➝ $1.50	High
8/5/2020	Barclays	Reiterated Rating	Hold		High
8/5/2020	BMO Capital Markets	Lower Target	Market Perform	$4.00 ➝ $2.00	High
8/4/2020	Piper Sandler	Downgrade	Neutral ➝ Underweight		High
5/19/2020	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight		Medium
5/6/2020	SVB Leerink	Boost Target	Market Perform	$2.00 ➝ $3.00	High
4/24/2020	Citigroup	Initiated Coverage	Sell		Low
4/2/2020	Barclays	Lower Target	Equal Weight	$5.00 ➝ $3.00	High
4/1/2020	Cfra	Lower Target	Hold	$6.00 ➝ $4.00	Low
2/26/2020	Bank of America	Boost Target	Underperform	$3.00	Low
1/22/2020	Wells Fargo & Company	Reiterated Rating	Hold		High
12/9/2019	Wells Fargo & Company	Reiterated Rating	Hold		Medium
10/9/2019	Wells Fargo & Company	Reiterated Rating	Hold		High
9/10/2019	Barclays	Set Target	Hold	$5.00	N/A
9/9/2019	Stifel Nicolaus	Lower Target	Hold	$20.00 ➝ $8.00	High
9/6/2019	Jefferies Financial Group	Set Target	Hold	$2.00	High
9/6/2019	SVB Leerink	Set Target	Hold	$2.00	High
9/5/2019	BMO Capital Markets	Reiterated Rating	Outperform ➝ Market Perform		High
9/4/2019	BMO Capital Markets	Downgrade	Outperform ➝ Hold	$3.00	Low
8/28/2019	Barclays	Lower Target	Equal Weight	$7.00 ➝ $5.00	Low
8/12/2019	SunTrust Banks	Lower Target	Hold ➝ Positive	$7.00	High
8/9/2019	Morgan Stanley	Set Target	Hold	$5.00	Low
8/7/2019	Stifel Nicolaus	Set Target	Hold	$20.00	High
8/7/2019	BMO Capital Markets	Set Target	Buy	$19.00	High
7/12/2019	Cantor Fitzgerald	Set Target	Buy	$18.00	Medium
7/11/2019	Jefferies Financial Group	Lower Target	Hold ➝ Reduce	$15.00 ➝ $10.00	Low
6/12/2019	Cantor Fitzgerald	Lower Target	Overweight	$42.00 ➝ $18.00	Low
6/11/2019	Barclays	Initiated Coverage	Equal Weight ➝ Equal Weight	$11.00	Low
6/6/2019	Wells Fargo & Company	Lower Target	Market Perform	$25.00 ➝ $11.00	Low
5/30/2019	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$39.00 ➝ $9.00	High
5/28/2019	Mizuho	Lower Target	Neutral	$22.00 ➝ $13.00	Low
5/24/2019	JPMorgan Chase & Co.	Lower Target	Neutral	$22.00 ➝ $11.00	High
5/22/2019	BMO Capital Markets	Reiterated Rating	Outperform	$23.00	High
5/22/2019	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$25.00 ➝ $15.00	High
5/21/2019	Berenberg Bank	Reiterated Rating	Sell	$10.00 ➝ $5.00	High
5/16/2019	Mizuho	Lower Target	Neutral	$25.00 ➝ $22.00	Medium
5/14/2019	SunTrust Banks	Set Target	Hold	$20.00	Low
3/19/2019	SunTrust Banks	Initiated Coverage	Hold ➝ Hold	$23.00	Medium
2/28/2019	Morgan Stanley	Set Target	Hold	$32.00	Low
2/28/2019	Mizuho	Boost Target	Neutral	$26.00	Low
12/31/2018	B. Riley	Lower Target	Neutral	$21.00	Low
12/17/2018	Mizuho	Reiterated Rating	Neutral ➝ Neutral		High
12/7/2018	Wells Fargo & Company	Set Target	Hold	$27.00	Medium
12/7/2018	Piper Jaffray Companies	Set Target	Buy	$39.00	High
11/13/2018	Mizuho	Boost Target	Neutral	$29.00	Low
11/7/2018	Berenberg Bank	Set Target	Sell	$23.00	Medium
11/6/2018	Wells Fargo & Company	Set Target	Hold	$27.00	High
11/6/2018	Mizuho	Reiterated Rating	Hold	$27.00	High
10/8/2018	Wells Fargo & Company	Set Target	Hold	$24.00	Low
9/14/2018	Berenberg Bank	Initiated Coverage	Sell	$25.00	High
9/11/2018	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$27.00 ➝ $28.00	Medium
8/24/2018	B. Riley	Boost Target	Neutral ➝ Neutral	$20.00 ➝ $37.00	Medium
8/22/2018	Wells Fargo & Company	Reiterated Rating	Hold		Low
8/17/2018	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $35.00	High
8/13/2018	SunTrust Banks	Boost Target	Hold ➝ Positive	$32.00	Low
8/8/2018	Wells Fargo & Company	Set Target	Market Perform ➝ Market Perform	$21.00 ➝ $30.00	High
8/8/2018	SVB Leerink	Boost Target	Market Perform	$12.00 ➝ $27.00	High
8/8/2018	Barclays	Boost Target	Underweight ➝ Underweight	$12.00 ➝ $20.00	High
8/8/2018	Stifel Nicolaus	Boost Target	Hold ➝ Hold	$18.00 ➝ $30.00	Medium
8/8/2018	Raymond James	Downgrade	Outperform ➝ Market Perform	$58.00	Medium
8/8/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$39.00	Low
8/7/2018	BMO Capital Markets	Reiterated Rating	Outperform	$37.00	Low
8/7/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$42.00	High
7/9/2018	Wells Fargo & Company	Boost Target	Market Perform ➝ Market Perform	$15.00 ➝ $21.00	High
6/28/2018	B. Riley	Boost Target	Neutral ➝ Neutral	$15.00 ➝ $20.00	Medium
6/19/2018	SunTrust Banks	Boost Target	Hold	$21.00	Low
6/18/2018	Stifel Nicolaus	Boost Target	Hold ➝ Hold	$15.00 ➝ $18.00	Low
5/15/2018	Oppenheimer	Reiterated Rating	Hold		Low
5/9/2018	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$27.00 ➝ $14.00	High
5/9/2018	Barclays	Set Target	Underweight ➝ Underweight	$20.00 ➝ $12.00	High
5/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$42.00	Medium
5/4/2018	Wells Fargo & Company	Set Target	Hold	$17.50 ➝ $15.00	Low
5/3/2018	Mizuho	Reiterated Rating	Hold	$15.00	Medium
5/2/2018	B. Riley	Initiated Coverage	Neutral ➝ Neutral	$15.00 ➝ $15.00	Low
4/30/2018	Cantor Fitzgerald	Set Target	Buy	$42.00	Low
4/26/2018	Mizuho	Reiterated Rating	Hold	$15.00	Low
4/23/2018	SVB Leerink	Lower Target	Market Perform		Low
4/20/2018	Mizuho	Reiterated Rating	Hold	$15.00	Low
4/12/2018	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$50.00	High
4/12/2018	Wells Fargo & Company	Reiterated Rating	Hold		High
4/11/2018	SunTrust Banks	Initiated Coverage	Hold	$15.00	High
4/2/2018	Cantor Fitzgerald	Set Target	Buy	$42.00	High
3/16/2018	Wells Fargo & Company	Set Target	Hold	$18.00	High
3/9/2018	Mizuho	Reiterated Rating	Neutral ➝ Neutral	$21.00 ➝ $16.00	Medium
2/27/2018	Oppenheimer	Reiterated Rating	Hold		High
2/27/2018	Cantor Fitzgerald	Set Target	Buy	$42.00	High
2/2/2018	Barclays	Downgrade	Equal Weight ➝ Underweight	$23.00 ➝ $20.00	Medium
1/9/2018	Mizuho	Reiterated Rating	Neutral ➝ Neutral	$22.00 ➝ $21.00	N/A
1/8/2018	Cantor Fitzgerald	Set Target	Buy	$42.00	Medium
1/2/2018	SVB Leerink	Initiated Coverage	Mkt Perform ➝ Market Perform	$26.00	Medium
1/1/2018	Wells Fargo & Company	Reiterated Rating	Hold		High
1/1/2018	The Goldman Sachs Group	Reiterated Rating	Hold		High
1/1/2018	Cantor Fitzgerald	Set Target	Buy	$42.00	High
12/26/2017	Cantor Fitzgerald	Set Target	Buy	$42.00	Low
12/26/2017	The Goldman Sachs Group	Reiterated Rating	Hold		Low
12/26/2017	Wells Fargo & Company	Reiterated Rating	Hold		Low
12/12/2017	Barclays	Set Target	Hold	$23.00	High

(Data available from 11/28/2017 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/2/2022

1 very positive mentions
1 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

6/1/2022

0 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/1/2022

0 very positive mentions
4 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

7/31/2022

0 very positive mentions
3 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

8/30/2022

0 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/29/2022

0 very positive mentions
3 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

10/29/2022

0 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/28/2022

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

finance.yahoo.com
11/8/2022
Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms Guidance
finance.yahoo.com
11/3/2022
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting
finance.yahoo.com
11/1/2022
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2022 Scientific Meeting
finanznachrichten.de
10/30/2022
Mallinckrodt plc: Mallinckrodt Receives Approval to List on NYSE American

Very Positive

No very positive mentions tracked during this time.

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Today's Range

Now: $11.40

$11.00

$11.40

50 Day Range

MA: $0.34

$0.14

$0.75

52 Week Range

Now: $11.40

$0.75

$6.42

Volume

7,336 shs

Average Volume

26,626 shs

Market Capitalization

$150.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Mallinckrodt?: The following sell-side analysts have issued reports on Mallinckrodt in the last twelve months:
View the latest analyst ratings for MNK.
What is the current price target for Mallinckrodt?: 0 Wall Street analysts have set twelve-month price targets for Mallinckrodt in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Mallinckrodt in the next year.
View the latest price targets for MNK.
What is the current consensus analyst rating for Mallinckrodt?: Mallinckrodt currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MNK.
What other companies compete with Mallinckrodt?: Other companies that are similar to Mallinckrodt include RVL Pharmaceuticals, Astria Therapeutics, LAVA Therapeutics, ORIC Pharmaceuticals and OptiNose. Learn More about companies similar to Mallinckrodt.
How do I contact Mallinckrodt's investor relations team?: Mallinckrodt's physical mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The company's listed phone number is (531) 696-0000 and its investor relations email address is [email protected] The official website for Mallinckrodt is www.mallinckrodt.com. Learn More about contacing Mallinckrodt investor relations.

Mallinckrodt - MNK Stock Price Target and Predictions

Analyst Price Target for MNK

Current Consensus is N/A

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.24 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Mallinckrodt?

What is the current price target for Mallinckrodt?

What is the current consensus analyst rating for Mallinckrodt?

What other companies compete with Mallinckrodt?

How do I contact Mallinckrodt's investor relations team?